Discovery Labs ( DSCO): Approval 47%; Rejection 49%; No decision 3%.
Astex Pharma ( ASTX): Approval 36%; Rejection 46%; No decision 18%.
NeurogesX ( NSGX): Approval 47%; Rejection 46%; No decision 7%.
MAP Pharma ( MAPP): Approval 37%; Rejection 59%; No decision 3%.
Affymax ( AFFY): Approval 68%; Rejection 22%; No decision 10%.
Chelsea Therapeutics ( CHTP): Approval 53%; Rejection 43%; No decision 3%.
Vivus ( VVUS) (Qnexa): Approval 49%; Rejection 39%; No decision 12%.
Amgen ( AMGN): Approval 53%; Rejection 42%; No decision 5%.
Vivus (Avanafil): Approval 76%; Rejection 19%; No decision 5%.
Note: Cell Therapeutics ( CTIC) was removed from the contest given the withdrawal of the pixantrone filing. One more note: One contestant has yet to get a single drug-approval decision correct. He/she is a lousy 0-4. I'll spare this person any further embarrassment by withholding their identity. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.